Investor profile · The Deep Pockets
Blackstone
The $6.3 Billion Life-Sciences Fund Built for Late-Stage Scale
Visit websiteWhy it made the list
Blackstone combines a record-scale dedicated life-sciences fund with a large late-stage product-financing platform built for capital-intensive clinical development.
Proof point
Blackstone closed BXLS VI at $6.3B on Mar. 30, 2026, calling it the largest private fund dedicated to life sciences; on Mar. 3, 2026 BXLS agreed to provide $400M to Teva for Phase 3 development of duvakitug.
Sources: blackstone.com, blackstone.com, blackstone.com
- Industry focus
- Pharmaceutical; Therapeutic; Medical Devices; MedTech
- Technology focus
- Agnostic
- Stage
- Late-Stage
- Geography
- United States
- Category
- The Deep Pockets
Team
Kiran Reddy, MD
Senior Managing Director, Blackstone Life Sciences
Paris Panayiotopoulos
Senior Managing Director, Blackstone Life Sciences
Nicholas Galakatos, PhD
Senior Managing Director, Global Head of Life Sciences
Is this investor a fit for you?
Assess your investment case and see which investors actually match your company.
Get Investor Ready